Araújo A, et al. An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer Rev Port Pneumol 2008; 14(6):803–827
Araújo A, et al. Avaliação económica do erlotinib, docetaxel, pemetrexedo e tratamento de suporte no tratamento de segunda ou terceira linhas de doentes com cancro do pulmão de não pequenas células Rev Port Pneumol 2008; 14(6):803–827
António Araújo
Read
851
Timeswas read the article
462
Total PDF
389
Total HTML
Share statistics
array:23 [ "pii" => "S2173511509701332" "issn" => "21735115" "doi" => "10.1016/S2173-5115(09)70133-2" "estado" => "S300" "fechaPublicacion" => "2009-05-01" "aid" => "70133" "copyright" => "Sociedade Portuguesa de Pneumologia" "copyrightAnyo" => "2009" "documento" => "simple-article" "crossmark" => 0 "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "cor" "cita" => "Rev Port Pneumol. 2009;15:560-6" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3360 "formatos" => array:3 [ "EPUB" => 180 "HTML" => 1807 "PDF" => 1373 ] ] "itemAnterior" => array:19 [ "pii" => "S2173511509701320" "issn" => "21735115" "doi" => "10.1016/S2173-5115(09)70132-0" "estado" => "S300" "fechaPublicacion" => "2009-05-01" "aid" => "70132" "copyright" => "Sociedade Portuguesa de Pneumologia" "documento" => "simple-article" "crossmark" => 0 "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "cor" "cita" => "Rev Port Pneumol. 2009;15:555-9" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 3338 "formatos" => array:3 [ "EPUB" => 188 "HTML" => 1786 "PDF" => 1364 ] ] "en" => array:8 [ "idiomaDefecto" => true "titulo" => "Araújo A, et al. An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer Rev Port Pneumol 2008; 14(6):803–827" "tienePdf" => "en" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "555" "paginaFinal" => "559" ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "Araújo A, <span class="elsevierStyleItalic">et al</span>. Avaliação económica do erlotinib, docetaxel, pemetrexedo e tratamento de suporte no tratamento de segunda ou terceira linhas de doentes com cancro do pulmão de não pequenas células Rev Port Pneumol 2008; 14(6):803–827" ] ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Wojciech Bartminski" "autores" => array:1 [ 0 => array:3 [ "preGrado" => "MD MSc" "nombre" => "Wojciech" "apellidos" => "Bartminski" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173511509701320?idApp=UINPBA00004E" "url" => "/21735115/0000001500000003/v1_201305151509/S2173511509701320/v1_201305151509/en/main.assets" ] "en" => array:9 [ "idiomaDefecto" => true "titulo" => "Araújo A, et al. An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer Rev Port Pneumol 2008; 14(6):803–827" "tieneTextoCompleto" => 0 "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "560" "paginaFinal" => "566" ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "António Araújo" "autores" => array:1 [ 0 => array:2 [ "nombre" => "António" "apellidos" => "Araújo" ] ] ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "Araújo A, <span class="elsevierStyleItalic">et al</span>. Avaliação económica do erlotinib, docetaxel, pemetrexedo e tratamento de suporte no tratamento de segunda ou terceira linhas de doentes com cancro do pulmão de não pequenas células Rev Port Pneumol 2008; 14(6):803–827" ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "bibliografia" => array:2 [ "titulo" => "Bibliography/Bibliografia" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:17 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Avaliação económica do erlotinib, docetaxel, pemetrexedo e tratamento de suporte no tratamento de segunda ou terceira linhas de doentes com cancro do pulmão de não pequenas células" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:1 [ 0 => "A. Araújo" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "Rev Port Pneumol" "fecha" => "2008" "volumen" => "14" "numero" => "6" "paginaInicial" => "803" "paginaFinal" => "827" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19023496" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "National Comprehensive Cancer Network. Practice Guidelines in Oncology – v.2.2009 Non-Small Cell Lung Cancer. Disponível em: <a class="elsevierStyleInterRef" href="http://www.nccn.org/professional/physician_gls/f_guidelines.asp">http://www.nccn.org/professional/physician_gls/f_guidelines.asp</a>. (consulta a 5 de Março de 2009 ." ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "National Institute for Health and Clinical Excellence. Updated guide to the methods of technology appraisal – June 2008. Disponível em: <a class="elsevierStyleInterRef" href="http://nice.org.uk/media/B52/A7/TAMethodsGuideUpsdatedJune2008.pdf">http://nice.org.uk/media/B52/A7/TAMethodsGuideUpsdatedJune2008.pdf</a>." ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Erlotinib in previously treated non-small cell lung cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "F.A. Shepherd" 1 => "J. Pereira" 2 => "T. Ciuleanu" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa050753" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2005" "volumen" => "353" "paginaInicial" => "123" "paginaFinal" => "132" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16014882" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib5" "etiqueta" => "5." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:1 [ 0 => "F.A. Shepherd" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/jco.2000.18.10.2095" "Revista" => array:6 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2000" "volumen" => "18" "numero" => "10" "paginaInicial" => "2095" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10811675" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib6" "etiqueta" => "6." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "N. Hanna" 1 => "F.A. Shepherd" 2 => "F.V. Fossela" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2004.08.163" "Revista" => array:6 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2004" "volumen" => "22" "paginaInicial" => "1589" "paginaFinal" => "1597" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15117980" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib7" "etiqueta" => "7." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A comparison of the estimated costs of erlotinib, docetaxel and pemetrexed for the second-line treatment of non-small cell lung cancer from the German healthcare perspective" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "W. Kotowa" 1 => "U. Gatzemeier" 2 => "O. Pirk" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Journal of Medical Economics" "fecha" => "2007" "volumen" => "10" "paginaInicial" => "255" "paginaFinal" => "271" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib8" "etiqueta" => "8." "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "National Institute for Health and Clinical Excellence. Pemetrexed for the treatment of non-small-cell lung cancer, August 2007. Disponível em: <a class="elsevierStyleInterRef" href="http://www.nice.org.uk/TA124">http://www.nice.org.uk/TA124</a>." ] ] ] 8 => array:3 [ "identificador" => "bib9" "etiqueta" => "9." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Chemotherapeutic management of stage IV non-small cell lung cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "M.A. Socinski" 1 => "D.E. Morris" 2 => "G.A. Masters" 3 => "R. Lilenbaum" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Chest" "fecha" => "2003" "volumen" => "123" "paginaInicial" => "226" "paginaFinal" => "243" ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib10" "etiqueta" => "10." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "New avenues for second-line treatment of metastatic non-small-cell lung cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "C. Gridelli" 1 => "P. Maione" 2 => "A. Rossi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1586/14737140.9.1.115" "Revista" => array:7 [ "tituloSerie" => "Expert Rev Anticancer Ther" "fecha" => "2009" "volumen" => "9" "numero" => "1" "paginaInicial" => "115" "paginaFinal" => "124" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19105711" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib11" "etiqueta" => "11." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Considerations for second-line therapy of non-small cell lung cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "T.E. Stinchcombe" 1 => "M.A. Socinski" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1634/theoncologist.13-S1-28" "Revista" => array:7 [ "tituloSerie" => "Oncologist" "fecha" => "2008" "volumen" => "13" "numero" => "Suppl 1" "paginaInicial" => "28" "paginaFinal" => "36" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18263772" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib12" "etiqueta" => "12." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cost-effectiveness of erlotinib <span class="elsevierStyleItalic">vs</span> docetaxel or pemetrexed in the treatment of refractory non-small cell lung cancer (NSCLC)" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "J. Carlson" 1 => "N. Oestreicher" 2 => "D.P. Lubeck" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Journal of Clinical Oncology" "fecha" => "2007" "volumen" => "25" "numero" => "Suppl 18 Pt I" "paginaInicial" => "425s" ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib13" "etiqueta" => "13." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Economic impact of second-and third-line erlotinib treatment of non small-cell lung cancer: a French observational study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "C. Chouaid" 1 => "A. Vergnenegre" 2 => "A. Moser" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Value in Health" "fecha" => "2007" "volumen" => "10" "paginaInicial" => "A322" ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib14" "etiqueta" => "14." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Economic evaluation of erlotinib, docetaxel and pemetrexed as seco nd line treatment in patients with advanced nonsmall-cell lung cancer (NSCLC): A cost-minimization in Italian hospitals" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "S. Capri" 1 => "A. Morabito" 2 => "G. Carillio" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Value in Health" "fecha" => "2007" "volumen" => "10" "paginaInicial" => "A333" ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib15" "etiqueta" => "15." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cost-minimization analysis of erlotinib versus docetaxel or pemetrexed as second-line therapy for non-small-cell lung cancer (NSCLC) from the perspective of a private payer in Brazil" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "S. Stefani" 1 => "M.G. Saggia" 2 => "E.A. Santos" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Value in Health" "fecha" => "2007" "volumen" => "10" "paginaInicial" => "A332k" ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib16" "etiqueta" => "16." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cost-effectiveness analysis of erlotinib compared with docetaxel and pemetrexed for second-line treatment of advanced non-small cell lung cancer (NSCLC) in Taiwan" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:3 [ 0 => "T.C. Hsia" 1 => "G.C. Chang" 2 => "Y.M. Chen" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Value in Health" "fecha" => "2007" "volumen" => "10" "paginaInicial" => "A325" ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib17" "etiqueta" => "17." "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pharmacoeconomic analysis of erlotinib compared with docetaxel for the treatment of relapsed non-small-cell lung cancer (NSCLC) in Turkey. PCN77" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "O. Batigun" 1 => "E. Yildrim" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Value in Health" "fecha" => "2007" "volumen" => "10" "paginaInicial" => "A234" ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/21735115/0000001500000003/v1_201305151509/S2173511509701332/v1_201305151509/en/main.assets" "Apartado" => array:4 [ "identificador" => "9639" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Reply to the Editor/Resposta ao Editor" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/21735115/0000001500000003/v1_201305151509/S2173511509701332/v1_201305151509/en/main.pdf?idApp=UINPBA00004E&text.app=https://journalpulmonology.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173511509701332?idApp=UINPBA00004E" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 4 | 1 | 5 |
| 2024 October | 34 | 25 | 59 |
| 2024 September | 25 | 28 | 53 |
| 2024 August | 44 | 33 | 77 |
| 2024 July | 23 | 28 | 51 |
| 2024 June | 19 | 26 | 45 |
| 2024 May | 26 | 30 | 56 |
| 2024 April | 18 | 19 | 37 |
| 2024 March | 24 | 14 | 38 |
| 2024 February | 23 | 28 | 51 |
| 2024 January | 15 | 27 | 42 |
| 2023 December | 15 | 20 | 35 |
| 2023 November | 12 | 30 | 42 |
| 2023 October | 12 | 33 | 45 |
| 2023 September | 24 | 30 | 54 |
| 2023 August | 12 | 13 | 25 |
| 2023 July | 17 | 28 | 45 |
| 2023 June | 12 | 14 | 26 |
| 2023 May | 20 | 24 | 44 |
| 2023 April | 10 | 11 | 21 |
Show all
